Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Men or women ≥ 18 and ≤ 75 years of age at time of screening~2. Stable moderate to severe plaque psoriasis for at least 6 months before baseline~3. Moderate to severe psoriasis defined at screening and baseline by:~   Body surface area (BSA) affected by plaque psoriasis of 10% or greater, and PASI score of 12 or greater, and static physician's global assessment score of 3 or greater~4. No known history of active tuberculosis~5. Subject is a candidate for systemic therapy or phototherapy procedures~6. Previous failure, inadequate response, intolerance, or contraindication to at least 1 conventional anti-psoriatic systemic therapy~Exclusion Criteria:~1. Forms of psoriasis or other skin conditions at the time of the screening visit (eg, eczema)~2. Ongoing use of prohibited treatments~3. Prior use of 2 or more biologics for treatment of psoriasis~4. Previous receipt of adalimumab or a biosimilar of adalimumab~Other Inclusion/Exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ABP 501 (Type: EXPERIMENTAL): Participants received 80 mg ABP 501 subcutaneously on week 1/day 1 (initial loading dose) and 40 mg at week 2 and every 2 weeks thereafter until week 16.~Participants with a PASI 50 response at week 16 continued to receive 40 mg APB 501 until week 48.
- Adalimumab (Type: ACTIVE_COMPARATOR): Participants received 80 mg adalimumab subcutaneously on week 1/day 1 (initial loading dose) and 40 mg at week 2 and every 2 weeks thereafter until week 16.~At week 16 participants with a PASI 50 response were re-randomized to treatment with adalimumab or were transitioned to ABP 501 until week 48.

Based on this trial design, predict the completion outcome and termination type (if applicable).